从癌症免疫周期角度探讨免疫检查点抑制剂的耐药性机制  

Mechanisms of Resistance to Immune Checkpoint Inhibitors from the Perspective of the Cancer Immunity Cycle

作　　者：胡睿歆 姜国辉 HU Ruixin;JIANG Guohui(Department of Pharmacy,Qingdao Mental Health Center,Qingdao,Shandong 266034,China;School of Pharmacy,Qingdao University,Qingdao,Shandong 266071,China)

机构地区：[1]青岛市精神卫生中心药剂科,山东青岛266034 [2]青岛大学药学院,山东青岛266071

出　　处：《中国医药指南》2025年第10期62-66,共5页Guide of China Medicine

摘　　要：近年来,肿瘤免疫治疗的快速发展为癌症患者提供了一种新的治疗选择。免疫检查点抑制剂(ICIs)是目前肿瘤免疫治疗的研究热点。ICIs包括细胞毒性T淋巴细胞相关抗原4(CTLA-4)、程序性死亡受体-配体1(PD-L1)和程序性死亡受体1(PD-1)单克隆抗体已被FDA批准用于肿瘤临床治疗,但其耐药性仍是一个需要解决的问题。癌症免疫周期(CIC)描述了抗肿瘤免疫反应的过程。在CIC中,免疫检查点PD-1、PD-L1和CTLA-4参与肿瘤的免疫逃逸并促进肿瘤进展。目前的研究主要集中在解决ICIs耐药性的潜在新策略上。然而,耐药涉及多种机制,这限制了ICIs的研究进展。本文回顾了CIC的步骤,并从CIC的角度总结了ICIs耐药的机制。Recently,fast-growing cancer immunotherapy provided a new treatment option for cancer.Immune checkpoint inhibitors(ICIs)are the current focus in cancer immunotherapy.ICIs including cytotoxic T lymphocyte-associated antigen-4(CTLA-4)、programmed cell death protein ligand 1(PD-L1)and programmed cell death protein 1(PD-1)monoclonal antibody have been approved by the FDA for cancer clinical treatment,but the mechanisms of resistance are still a great problem to overcome.The cancer immunity cycle(CIC)revealed the processes of anti-tumor immune responses.In the cancer immunity cycle,the immune checkpoints PD-1,PD-L1,and CTLA-4 are involved in the immune escape of tumors and promote tumor progression.Current research focuses on new potential strategies to overcome resistance to ICIs.Nevertheless,multiple mechanisms are involved in resistance which limits the progress of research on ICIs.In this review,we resumed the steps of the cancer immunity cycle and summarized possible mechanisms of ICIs from the perspective of the cancer immunity cycle.

关 键 词：肿瘤免疫治疗 免疫检查点抑制剂 耐药机制 癌症免疫周期 

分 类 号：R730.5[医药卫生—肿瘤]